LifeMD: Leveraging Exclusive Oral Wegovy Access and Telehealth Scale to Capture GLP-1 Weight-Loss Upside

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on LifeMD. The associated price target remains the same with $9.00.

Yi Chen has given his Buy rating due to a combination of factors tied to LifeMD’s strategic positioning in the rapidly growing GLP-1 weight-loss market and the attractive economics of its new offering. LifeMD is now providing access to Novo Nordisk’s newly approved oral Wegovy pill—currently the only FDA-approved oral GLP-1 for chronic weight management—through its nationwide telehealth platform. By leveraging an agreement that enables competitive cash-pay pricing, LifeMD can offer multiple Wegovy pill dosages at relatively low monthly prices, which Chen believes should broaden access for uninsured or underinsured patients and drive incremental demand. The company’s integrated model, which combines virtual physician visits and streamlined access to GLP-1 prescriptions via NovoCare Pharmacy, further supports a differentiated patient experience that could translate into higher patient acquisition and retention over time.
Chen also highlights the strong clinical profile of the oral Wegovy pill, whose pivotal Phase 3 data showed weight loss outcomes that outperform other oral GLP-1 candidates, reinforcing the attractiveness of LifeMD’s offering. From a valuation standpoint, his 12‑month price target of $9 is based on a peer comparison framework using EV/Revenue multiples applied to projected sales over the next year, suggesting meaningful upside from current levels. While acknowledging risks such as execution challenges in scaling telehealth revenue, competition, profitability hurdles, and potential dilution, Chen judges that the growth potential associated with the GLP-1 expansion and LifeMD’s favorable pricing and distribution arrangements outweigh these concerns, supporting a continued Buy recommendation.

In another report released yesterday, Lake Street also maintained a Buy rating on the stock with a $8.00 price target.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LFMD in relation to earlier this year.